CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
NVX-CoV2372biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06027229
NCT06027229Phase 2Completed
CompareCT.gov

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

University of Wisconsin, Madison·interventional·Posted Sep 7, 2023·Updated Oct 20, 2025

In Brief

A Phase 2 clinical trial evaluating NVX-CoV2372 for Immunosuppression and COVID-19. Completed, enrolled 21 participants across 1 site.

Detailed Summary

To determine whether providing a recombinant booster COVID-19 vaccine improves sustained humoral and cell-mediated immunogenicity against SARS-CoV-2 in immunosuppressed patients with Inflammatory Bowel Disease (IBD) and/or solid organ transplant recipients. 120 participants will be enrolled and can expect to be on study for 6 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunosuppression, COVID-19
CountriesUnited States
CollaboratorsNovavax

Timeline

Phase 2CompletedFinished
202420252026
First PostedSep 7, 2023
Enrollment StartNov 20, 2023
Primary CompletionApr 24, 2024
Study CompletionSep 9, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.8 years ago

Interventions

NVX-CoV2372biological

Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5